Investigation of Natural WT1-specific and PRAME-specific Immunity in Ovarian Cancer

Investigation of Natural WT1-specific and PRAME-specific Immunity in Ovarian Cancer - WT1 and PRAME immunity in ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40116

Enrollment

Registered

2013-04-22

Start date

2013-09-18

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - women newly diagnosed with epithelial ovarian cancer; prior to treatment or after neoadjuvant chemotherapy prior to cytoreductive surgery - adequate venous access for blood collection - 18 years of age or older - informed consent

Exclusion criteria

Exclusion criteria: - previous or concurrent malignancies, other than basal or planocellular cancer of the skin - concurrent immunosuppressive therapy, other than chemotherapy for ovarian cancer - recurrent epithelial ovarian cancer

Design outcomes

Primary

Measure	Time frame
Quantification and qualitative analysis of WT1-specific and PRAME-specific cellular and humoral immunity in patients with EOC during standard therapy.	—

Countries

Netherlands

Outcome results